香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-190 江苏恒瑞医药股份有限公司 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年11月27日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生 ...

Core Insights - The article highlights the top and bottom AH premium rates for various stocks as of November 27, with Northeast Electric (00042) leading with a premium rate of 864.29% [1] - The article also lists the stocks with the highest and lowest deviation values, indicating significant discrepancies between A-shares and H-shares [1] AH Premium Rate Rankings - The top three stocks with the highest AH premium rates are: - Northeast Electric (00042): 864.29% - Hongye Futures (03678): 269.82% - Sinopec Oilfield Service (01033): 264.86% [1] - The bottom three stocks with the lowest AH premium rates are: - Ningde Times (03750): -5.40% - China Merchants Bank (03968): -1.65% - Heng Rui Medicine (01276): -0.38% [1] Deviation Value Rankings - The stocks with the highest deviation values are: - Vanke Enterprises (02202): 30.48% - Dazhong Public Utilities (01635): 24.57% - Shandong Xinhua Pharmaceutical (00719): 22.88% [1] - The stocks with the lowest deviation values are: - Sairis (09927): -17.06% - China National Airlines (00753): -13.21% - China Life (02628): -13.18% [1] Additional Insights - The article provides detailed tables showing the premium rates and deviation values for the top and bottom AH stocks, indicating market trends and potential investment opportunities [2]

Group 1 - Wellington Management Group LLP increased its stake in 恒瑞医药 (Hengrui Medicine) by acquiring 1 million shares at an average price of HKD 69.15 per share, totaling approximately HKD 69.15 million [1] - Following this transaction, Wellington Management Group LLP's total shareholding rose to 21.48 million shares, increasing its ownership percentage from 7.93% to 8.32% [1][2]

Core Viewpoint - Wellington Management Group LLP increased its stake in Heng Rui Pharmaceutical (01276) by purchasing 1 million shares at a price of HKD 69.15 per share, totaling HKD 69.15 million, raising its total holdings to approximately 21.48 million shares, which represents an ownership percentage of 8.32% [1] Summary by Category - **Investment Activity** - Wellington Management Group LLP acquired 1 million shares of Heng Rui Pharmaceutical at HKD 69.15 per share, amounting to HKD 69.15 million [1] - Post-transaction, Wellington's total shareholding in Heng Rui Pharmaceutical is approximately 21.48 million shares [1] - **Ownership Structure** - Following the increase, Wellington Management Group holds an 8.32% stake in Heng Rui Pharmaceutical [1]

Core Insights - The article highlights the top and bottom AH premium rates for various stocks, indicating significant discrepancies between H-shares and A-shares [1][2][3] Group 1: Top AH Premium Rates - Northeast Electric (00042) leads with an AH premium rate of 831.03%, followed by Sinopec Oilfield Service (01033) at 267.57% and Hongye Futures (03678) at 266.67% [1][2] - Other notable stocks with high premium rates include Zhejiang Shibao (01057) at 263.21% and Fudan Zhangjiang (01349) at 237.83% [2] Group 2: Bottom AH Premium Rates - The stocks with the lowest AH premium rates include Ningde Times (03750) at -4.42%, China Merchants Bank (03968) at -1.39%, and Hengrui Medicine (01276) at 1.55% [1][2] - Additional stocks with low premium rates are WuXi AppTec (02359) at 5.00% and Weichai Power (02338) at 6.47% [2] Group 3: Top Deviation Values - The highest deviation values are seen in China Shipbuilding Defense (00317) at 27.44%, Shandong Xinhua Pharmaceutical (00719) at 22.88%, and Guanghetong (00638) at 22.39% [1][3] - Other stocks with significant deviation values include Nanjing Panda Electronics (00553) at 16.09% and Vanke Enterprises (02202) at 15.80% [3] Group 4: Bottom Deviation Values - Northeast Electric (00042) has the lowest deviation value at -25.74%, followed by Longpan Technology (02465) at -16.99% and Air China (00753) at -13.49% [1][3] - Additional stocks with low deviation values include Jiangsu Ninghu Expressway (00177) at -12.27% and China Life (02628) at -11.52% [3]

Core Viewpoint - Heng Rui Medicine (01276.HK) has received approval from the National Medical Products Administration for the clinical trial of HRS-8364 tablets, which will commence shortly [1] Group 1 - The company has announced the approval of a clinical trial for HRS-8364 tablets [1] - The clinical trial is expected to start in the near future [1]

Group 1 - The core point of the article is that Heng Rui Pharmaceutical (01276.HK) has seen its stock price increase by over 5%, specifically by 5.61%, reaching a price of 74.3 HKD [1] - The trading volume for Heng Rui Pharmaceutical is reported at 126 million HKD [1]

Core Viewpoint - Heng Rui Medicine (01276) experienced a stock price increase of over 5%, currently up 5.61% at HKD 74.3, with a trading volume of HKD 126 million [1] Group 1: Clinical Trial Approvals - On November 25, Heng Rui Medicine announced the approval from the National Medical Products Administration for two drug clinical trial notifications [1] - The HRS-8364 tablet will soon commence clinical trials for advanced solid tumors, with no similar drugs approved for market domestically or internationally [1] - Cumulative R&D investment for the HRS-8364 project is approximately RMB 21.65 million [1] Group 2: Additional Drug Development - The injectable Rukang Trastuzumab will also begin clinical trials for patients with HER2-positive solid tumors [1] - Cumulative R&D investment for the injectable Rukang Trastuzumab project is around RMB 1.41 billion [1]

Core Insights - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of injection-based Rukang Qutuzumab [1] - The drug is set to be launched in China in May 2025, targeting adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have HER2 (ERBB2) activating mutations and have previously received at least one systemic treatment [1] Group 1 - Rukang Qutuzumab works by binding to HER2-expressing tumor cells, leading to internalization and release of toxins in the tumor cell lysosome, which induces cell cycle arrest and triggers tumor cell apoptosis [2] - The released toxins exhibit high membrane permeability and can exert bystander killing effects, enhancing anti-tumor efficacy [2] - Similar products already on the market include Roche's Ado-trastuzumab emtansine and AstraZeneca's Fam-trastuzumab deruxtecan, both of which have been launched in China [2] Group 2 - The global sales of similar products are projected to reach approximately $6.557 billion from 2024 onwards [2] - The cumulative R&D investment for Rukang Qutuzumab has reached approximately 141.475 million yuan [2]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-8364 tablets, an innovative anti-tumor drug developed by the company, aimed at treating advanced solid tumors [1] Group 1: Product Development - HRS-8364 tablets are a self-developed innovative anti-tumor drug [1] - The drug is intended for the treatment of advanced solid tumors [1] - Currently, there are no similar drugs approved for sale in both domestic and international markets [1] Group 2: Financial Investment - The total research and development investment for the HRS-8364 project has reached approximately 21.65 million yuan [1]